Ultragenyx Pharmaceutical Inc
(NAS:RARE)
$
57.87
1.5 (2.66%)
Market Cap: 5.33 Bil
Enterprise Value: 4.46 Bil
PE Ratio: 0
PB Ratio: 12.33
GF Score: 74/100 
Ultragenyx Pharmaceutical Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023 / 04:20PM GMT
Release Date Price:
$48.58
(+3.21%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Good morning. Welcome to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior SMid biotech analysts here. It's my pleasure to have our next presenting company with us, Ultragenyx. With me from Ultragenyx is President and CEO, Emil Kakkis. Emil, welcome back to Las Vegas.
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director
Thanks for having me here.
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
So it's always good to catch up with you. Maybe just give us a 2-minute overview of the company and then we can go into the specifics of our questions.
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director
Sure, Tazeen. Well, Ultragenyx is now 13 years in from founding. And in those years, we have 4 approvals and 3 products generating into
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers